OlegEAkilovMDPhD

Dermatology • Pittsburgh, PA

Assistant Professor of Dermatology; Director, Cutaneous Lymphoma Program

Join to view full profile

Dr. Akilov is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Akilov's full profile

Already have an account?

Office
200 Lothrop St
# Univ
Pittsburgh, PA 15213
Phone+1 412-647-4200

Fax+1 412-864-3740

Education & Training

UPMC Medical EducationResidency, Dermatology, 2012 - 2015
UPMC Medical EducationChief Residency, Dermatology, 2014 - 2014
University of ColoradoInternship, Surgery, 2011 - 2012
UPMC Medical Education/Presbyterian Shadyside HospitalFellowship, Cutaneous Oncology, 2009 - 2011
Ural State Medical AcademyClass of 1998

Certifications & Licensure

PA State Medical License 2009 - 2024
CO State Medical License 2011 - 2014
American Board of Dermatology Dermatology

Clinical Trials

Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research Start of enrollment: 2004 Oct 01
Recruiting

Publications & Presentations

PubMed

Maintenance therapy for CTCL: importance for prevention of disease progression.
Emily R Gordon, Megan H Trager, Bradley D Kwinta, Connor J Stonesifer, Kaitlyn J Lee
Leukemia & Lymphoma. 2024-12-01
A Retrospective Cohort Study to Determine Real-World Treatment Patterns in Patients with Sézary Syndrome in the United States.
Robert Ristuccia, Yang Zhao, Chunlan Chang, Huanxue Zhou, Takeshi Takahashi
Oncology and Therapy. 2024-12-01
Unleashed monocytic engagement in Sézary syndrome during the combination of anti-CCR4 antibody with type I interferon.
Tony T Jiang, Oleg Kruglov, Oleg E Akilov
Blood Advances. 2024-05-28

Lectures

Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPαFc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the P...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018